## HOLX: Hologic, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.2% below STRENGTH zone (4.0-10.0%); PEG 1.65 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (54% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.04)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Smart Oncology: 5 Stocks Chasing the $317B Prize**
- Source: Morningstar | 20251231T120849 | Somewhat-Bullish | Relevance: 93%
- The precision oncology market is rapidly expanding, driven by advancements in biomarker-guided therapies and AI. This article highlights five key players—Oncolytics Biotech Inc., Exact Sciences Corp., Veracyte, Inc., Hologic, Inc., and Personalis, Inc.—that are at the forefront of this $317 billion industry. These companies are developing innovative solutions for cancer diagnosis and treatment, offering new hope for personalized and effective care.

**2. Smart Oncology: 5 Stocks Chasing the $317B Prize**
- Source: The Globe and Mail | 20260101T070905 | Somewhat-Bullish | Relevance: 71%
- The precision oncology market is rapidly expanding, projected to reach $317.5 billion by 2035, driven by a shift towards biomarker-guided cancer treatments. This article highlights five companies – Oncolytics Biotech Inc., Exact Sciences Corp., Veracyte, Inc., Hologic, Inc., and Personalis, Inc. – that are poised to capitalize on this significant growth by focusing on diagnostic precision and therapeutic targeting.

**3. Abbott Laboratories (ABT): Buy, Sell, or Hold Post Q3 Earnings?**
- Source: Finviz | 20251231T230400 | Neutral | Relevance: 56%
- Abbott Laboratories (ABT) shares have declined by 7.9% over the past six months, prompting investor reevaluation. The company benefits from economies of scale and robust free cash flow margins, averaging 16.8% over five years. However, its long-term revenue growth has been a mediocre 6.4% compounded annually over the same period.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 15 ($0.00M) |
| Sells | 26 ($6.64M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-2.2%)
- T. Rowe Price Invest: 9.7% (-10.5%)
- Blackrock Inc.: 8.7% (-2.7%)
- Manufacturers Life I: 4.7% (-5.2%)
- State Street Corpora: 4.5% (-1.2%)

### Key Risks

1. Insider selling cluster: $6.6M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +1.7% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.65 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (3.8x). Insider selling cluster ($6.6M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 8 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.6B |
| Beta | 0.70 |
| 52W Range | $51.90 - $75.34 |
| Short Interest | 2.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.65 |
| Forward P/E | 14.9 |
| Current P/E | 16.4 |
| YoY Growth | 9.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.4% to 0.2% (+1.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.8pp (needs >4.0% for momentum thesis). MRS_5 at 0.7% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.12x) but short-term weakness (below SMA20). RSI neutral at 51. Volume at 54% of 20MA suggests lack of conviction. OFD pattern: +DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.23% (CS: 42) | Neutral |
| RSI_14 | 51.1 | Neutral |
| MACD Histogram | -0.13 | Bearish |
| vs SMA20 | 0.997x | Below |
| vs SMA50 | 1.001x | Above |
| vs SMA200 | 1.124x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $74.56
- **Stop Loss:** $74.04 (0.7% risk)
- **Target:** $75.08 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 2769
- **Position Value:** $206,456.64
- **Portfolio %:** 206.46%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-04 (Est: $1.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.10 | $1.13 | +2.7% |
| 2025Q2 | $1.05 | $1.08 | +2.7% |
| 2025Q1 | $1.02 | $1.03 | +1.4% |
| 2024Q4 | $1.02 | $1.03 | +1.4% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*